Celgene, bluebird partner on CAR-T therapy

Mar 28, 2018

Celgene and bluebird bio have agreed to co-commercialize and co-promote an investigational cell therapy treatment known as bb2121 in the United States.

Through the collaboration, the companies hope to develop the cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma. Last December, the two companies announced promising updated results from a small Phase 1 clinical study of bb2121.

The companies originally entered into a broad, global strategic research collaboration in 2013 to discover, develop and commercialize novel therapies in oncology, which included bb2121.

Read the press release